Slide 1: Corporate Presentation: Financial Results H1 FY 2006
Corporate Presentation Financial Results H1 FY 2006
Slide 2: Disclaimer
Disclaimer BS Biocon Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking st
Slide 3: Performance Highlights: H1 FY06
$ BIocon Performance Highlights : H1 — FY 06 revenusRS. 3/5 CYS patRS.82 Crs e¢ Consolidated revenues grew by 4% over H1- FY 05. ¢ Operating profits fell by 8% over H1- FY 05. e Profit after Tax showed a 22% decline over H1 — FY 05 e PAT margins maintained at a healthy 22%. ¢ Operating results were
Slide 4: Performance Highlights: H1 FY06
Bj Performance Highlights : H1 — FY 06 cS focon revenusRS. 3/5 CYS patRS.82 Crs e Research Services, Enzymes, Insulin and other Bio-pharmaceutical products performed strongly. e Good progress maintained on Biocon’s discovery led Diabetes and Oncology research programs. e The SEZ application for Bioc
Slide 5: Revenue by segment H1 FY05 vs H1 FY06
367 377 287 291 44 42 42 29 7 2 H1 FY 05 H1 FY 06 Custom Research Enzymes Pharma Other Income Total
Slide 6: H1 Revenues, EBIDTA, PBT and PAT
Particulars H1- 05 % on H1- 06 % on Revenues Revenues Revenues 367 377 EBIDTA 122 33% 112 32% PBT 113 30% 98 26% Tax 8 2% 16 4% PAT 105 29% 82 22%
Slide 7: Quarterly Revenues, EBIDTA, PBT and PAT
% on % on Particulars Q1 -06 Q 2 - 06 Revenues Revenues Revenues 176 202 EBIDTA 52 30% 60 30% PBT 45 26% 53 26% Tax 7 4% 9 5% PAT 39 22% 44 22%
Slide 8: Outlook
Outlook • Discovery-led research programs in Diabetes and Oncology making good progress. • Pre-clinical studies for Oral Insulin (IN105) is in progress. • IN105 data presented for the first time at EASD. • IND for IN105 is expected to be submitted by the end of this fiscal. • Phase IIB clinical tria
Slide 9: Effectiveness of an Insulin Developed for Oral Delivery
logic Effectiveness of an Insu Developed for Oral Insu Margaret Lautz‘, Carrie Everett, Ben Farmer’, Melanie Scott!, Gordana Kosutic?, Karen Polowy?, Radha Krishnan?, and 9 =NOBEX Alan D. Cherrington’ $Biocon 41Vanderbilt University School of Medicine, Nashville, TN USA and Nobex Corporation, Resear
Slide 10: Thank You
Thank You